Effect of bromocriptine on 6-hydroxydopamine-induced lipid peroxidation and cytotoxicity in vitro and in vivo.
- Author:
Yong Sik KIM
;
Sungho MAENG
;
Chan Woong PARK
- Publication Type:In Vitro ; Original Article
- MeSH:
3,4-Dihydroxyphenylacetic Acid;
Antioxidants;
Brain;
Bromocriptine*;
Cell Line;
Dopamine;
Dopamine Agonists;
Humans;
Lipid Peroxidation*;
Neuroblastoma;
Oxidopamine;
Parkinson Disease
- From:The Korean Journal of Physiology and Pharmacology
1998;2(5):565-572
- CountryRepublic of Korea
- Language:English
-
Abstract:
The present study was to evaluate the protective effects of bromocriptine, which is known as D2 dopamine receptor agonist and used for the treatment of patients with Parkinson's disease (PD), on 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in vitro and in vivo. Lipid peroxidation product (malondialdehyde; MDA) produced by the administration of 6-OHDA was profoundly reduced following the treatment of bromocriptine in a dose-dependent manner in rabbit brain homogenate. Quinone formation by 6-OHDA autoxidation was also attenuated, and its effect was as potent as other antioxidants. Pretreatment of bromocriptine reduced the cytotoxicity of 6-OHDA on SH-SY5Y neuroblastoma cell lines dose-dependently. The loss of striatal dopamine and its metabolite, DOPAC (dihydroxyphenylacetic acid) as well as increase of MDA production caused by intrastriatal injection of 6-OHDA was significantly recovered following the treatment of bromocriptine. The present study clearly showed that bromocriptine had a protective action against 6-OHDA-induced neurotoxicity. These results suggest that bromocriptine has the antioxidant properties, which could be another advantage for delaying the progress of Parkinson's disease.
